期刊文献+

肺癌P53表达与临床病理特征及预后关系的研究 被引量:2

Relationship between expression of P53 in lung cancer and clinical pathological characteristics as well as prognosis
下载PDF
导出
摘要 目的探讨大、小细胞肺癌中P53的表达及其在肺癌发生、转移以及预后中的意义。方法采用S-P免疫组化染色技术及显微分光光度术,检测86例肺癌P53的表达情况。结果肺癌P53的表达与肺癌淋巴结转移及临床分期有关,P53的表达与患者的生存率有关,但与组织学分级及分化程度无关。P53阳性率及强度,在肺癌伴淋巴结转移阳性组高于淋巴结转移阴性组(P<0.01)。随着临床分期的增高,阳性率逐渐增高(P<0.05)。P53阳性患者术后3年生存率明显低于阴性者(P<0.05)。结论对肺癌进行P53的检测,有助于预测肺癌进展程度和淋巴结转移的诊断,以及评估肺癌患者的预后。 Objective To investigate the expression of P53 in lung cancer and its clinical significance in the carcinogenesis,metastasis and prognosis of lung cancer.Methods The expressions of P53 in 86 patients with lung cancer were detected by SP immunohistochemistry and microspectrophotometry.Results The expression of P53 was related with the lymph node involvement rate and related with the TNM classification.The positive rate of P53 was higher in positive lymph node group than that in negative lymph node group ( P <0.01).The later the pathologic stage,the lower the positive rate ( P <0.05).The 3-year survival rate in patients with P53-positive was lower than that of patients with P53-negative ( P <0.05).Conclusion The determination of P53 may contribute to assessing tumor progression and lymphatic metastasis and predicting prognosis of patients with lung cancer.
出处 《河北医药》 CAS 2005年第5期325-326,共2页 Hebei Medical Journal
基金 天津市卫生局科技基金资助(编号:96KY-GG18)
关键词 肺癌 P53 表达 病理特征 预后 lung cancer P53 immunohistochemistry metastasis prognosis
  • 相关文献

参考文献7

  • 1Beenken SW,Grizzle WE,Crowe DR,et al.Molecular biomarkers for breast cancer prognosis:coexpression of cerbB-2 and P53.Ann Surg,2001,233:630-638.
  • 2Korkolis D,Ardavanis A,Yotis J,et al.Her-2/neu overexpression in breast cancer:an immunohistochemical study including correlations with clinicopathologic parameters,P53 oncoprotein and cathepsin-D.Anticancer Res,2001,21:2207-2212.
  • 3Brambilla E,Gazzeri S,Moro D,et al.Immunohistochemical study of P53 in human lung carcinomas.Am J Pathol,1993,143:199-220.
  • 4Marchetti A,Buttitta F,Merlo G,et al.P53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.Cancer Res,1997,53:2846-2851.
  • 5Mishina T,Dosaka AH,Hommura F,et al.Cyclin E express,a potential prognostic marker for non-small cell lung cancers.Clin Cancer Res,2000,6:11-16.
  • 6张娟辉,丁彦青,周新力,孔欣,蔡俊杰,施玉兰.卵巢囊腺癌PCNA、P53蛋白表达及AgNORs图像分析临床意义[J].中国全科医学,2003,6(6):467-469. 被引量:2
  • 7Norberg T,Klaar S,Karf G,et al.Increased P53 mutation frequency during tumor progression-results from a breast cancer cohort.Cancer Res,2001,61:8317-8321.

二级参考文献8

  • 1Henriksen RS, trang P, Wilander E, et al. P 53 expression in epithelial ovarian neoplasms: relation - ship to clinical and pathological parameters, Ki - 67 expression and flow cytometry. Gynecol - Oncol,1994, 53 (3): 301-306.
  • 2Kappes - S. P 53 mutations in ovary tumors, detected by temperature-gradient gelelectrophoresis, directsequencing and immunohistochemisty.Int-J-Cnacer, 1995, 64 (1): 52-59.
  • 3Kupryjanczyk - J, Bell - DA, Yandell - DW. P 53 expression in ovarian borderline tumors and stage Icacinomas. Am - j - Clin - Pathol,1994, 102 (5): 671-676.
  • 4Jun Jiecai, Hong Mingqiu. Aplication of vaccumcabinal in immunohistochemicalstainability. Cell vision, 1995, 2 : 142 - 143.
  • 5Yamanaka S, Nagai N, Ohanak. Study of proliferating cell nuclear antigen (PCNA) nucleolar organizer regions (NORs) and mitotic activity in epithelial ovarian tumors. Nippon Sanka Fuginka Gakkai Iasshi,1993, 45 (3): 234-240.
  • 6Muhammad S, Shunbaji, Sandra, et al. Proliferrating cell nuclear antigen immunoreactivity in cervical intraepithelial neoplasis and benign cevical epithelium. Anut Pathol, 1993, 100:23 -27.
  • 7Criscouoto M, Martinelli M, Migaldi M, et al. Prognostic signicance of nuclear regions in ovarian epithelial tumors. Int J Gynecol Parthol,1993, 12 (3): 259-263.
  • 8蔡俊杰,邱红明,张盛.应用真空负压LSAB法快速显示各种组织相关抗原的研究[J].中国组织化学与细胞化学杂志,1996,5(1):109-111. 被引量:6

共引文献1

同被引文献11

  • 1孙燕妮,李强,刘忠令,白冲,韩一平,黄怡,赵立军,姚小鹏.野生型p53基因转染对人肺腺癌细胞系A549 VEGF表达和肿瘤生长的影响[J].第四军医大学学报,2004,25(15):1389-1393. 被引量:2
  • 2Oshita F, Kameda Y, Hamanaka N, et al. High Expression of Integrin 131 and p53 is a Greater Poor Prognostic Factor Than Clinical Stage in Small-Cell Lung Cancer[J]. A J Clin Onc, 2004,27(3):215 -219.
  • 3Qian Y,Luckey C,Horton L,et al.Biological function of the retinoblastoma orotein requires distinct domains for hyperphosphorylation and transcription factor binding.Mol Cell Biol,1992,12:5363.
  • 4Qin XQ,Chittenden.Tumor suppressor genes.Science,1992,6:953.
  • 5Weinberg RA.Tumor suppressor genes.Science,1991,:254:1138.
  • 6Horowitz JM,Yandell DW,Park SH,et al.Piont mutational inactivation of the retinoblastoma antioncogene.Science,1989,243:937.
  • 7周际昌主编.实用肿瘤内科学.第2版.北京:人民卫生出版社,2005.549
  • 8Levine AJ.P53 tumor suppressor gene and product.Cancer Surv,1992,12:59.
  • 9Matsuzoe D,Hideshima T,Kimura A,et al.P53 mutations predict non-small cell lung carcinoma response to radiotherapy.Cancer Lett,1999,135:189-194.
  • 10孟宇宏,李维华.肺和胸膜肿瘤的组织学分类[J].诊断病理学杂志,2000,7(2):156-157. 被引量:13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部